Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
21 8월 2023 - 8:00PM
Business Wire
- Mr. Weinand is the former CEO and Chairman of the Board at
Bayer Pharma AG, leading Bayer’s fully integrated $20 billion
healthcare business
- Mr. Weinand is a seasoned business leader with over 25 years of
experience leading business and strategic operations for companies
including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and
Otsuka
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics and cell therapies intended to enhance the function of
Regulatory T Cells (Tregs), today announced that it has appointed
Mr. Dieter Weinand to its board of directors, effective
immediately. Coya will leverage Mr. Weinand’s extensive experience,
connections, and judgement to guide Coya’s strategic discussions
and development programs.
“I am delighted to join the board of Coya, a company whose
science has the potential to make a significant clinical difference
in patients’ lives suffering from difficult to treat
neurodegenerative diseases, an experienced leadership team that I
believe can unlock the full potential of the therapies, and a
cohesive board of directors. I look forward to becoming a part of
this remarkable company,” Mr. Weinand commented.
“Coya has strengthened its DNA with Dieter. Having his counsel,
guidance, and network available to Coya at this time will bolster
our profile in 'big picture’ opportunities including business
development and strategic discussions. His selection to join Coya
at this point in his career is a validating moment for us,” stated
Howard Berman, Ph.D, CEO of Coya.
Dieter Weinand is an experienced executive with over 25 years of
experience in the pharmaceuticals and biotech industries. Mr.
Weinand presently serves as the Chairman of the Board of Directors
of Replimune Group Inc. (NASDAQ: REPL), Mnemo Therapeutics, Umoja
Biopharma, Inc., Inspirna, Inc., and Ziel Bio, Inc. Previously, Mr.
Weinand was Chief Executive Officer and Chairman of the Board of
Bayer Pharma AG and member of the Management Board at Bayer AG.
Prior to his work at Bayer, Mr. Weinand held various positions in
commercial, operational, and strategic areas of the pharmaceutical
industry. These included responsibilities spanning various
therapeutic areas and geographies for companies such as Pfizer,
Bristol Myers Squibb, and Otsuka. Mr. Weinand is a former board
member of the Pharmaceutical Research and Manufacturers of America
(PhRMA), the European Federation of Pharmaceutical Industries &
Associations (EFPIA), and the International Federation of
Pharmaceutical Manufacturers (IFPMA), and served as a member of the
Board of Directors of HealthPrize Technologies.
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead therapeutic
programs includes Treg-enhancing biologics (COYA 300 Series product
candidates) COYA 301 and COYA 302, which are intended to enhance
Treg function and expand Treg numbers. COYA 301 is a proprietary
investigational recombinant human low dose IL-2 biologic for
subcutaneous administration intended to enhance Treg function and
expand Treg numbers in vivo, and COYA 302 is a dual-mechanism
investigational biologic combination comprised of proprietary low
dose IL-2 and proprietary CTLA4 Ig. The low dose IL-2 is intended
to enhance anti-inflammatory regulatory T cell function and numbers
while the fusion protein CTLA4 Ig is intended to suppress
pro-inflammatory cell function. These two mechanisms may be
additive or synergistic in suppressing inflammation. For more
information about Coya, please visit www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to known and
unknown risks, uncertainties, assumptions and other factors
including, but not limited to, those related to risks associated
with the impact of COVID-19; the success, cost and timing of our
product candidate development activities and ongoing and planned
clinical trials; our plans to develop and commercialize targeted
therapeutics; the progress of patient enrollment and dosing in our
preclinical or clinical trials; the ability of our product
candidates to achieve applicable endpoints in the clinical trials;
the safety profile of our product candidates; the potential for
data from our clinical trials to support a marketing application,
as well as the timing of these events; our ability to obtain
funding for our operations; development and commercialization of
our product candidates; the timing of and our ability to obtain and
maintain regulatory approvals; the rate and degree of market
acceptance and clinical utility of our product candidates; the size
and growth potential of the markets for our product candidates, and
our ability to serve those markets; our commercialization,
marketing and manufacturing capabilities and strategy; future
agreements with third parties in connection with the
commercialization of our product candidates; our expectations
regarding our ability to obtain and maintain intellectual property
protection; our dependence on third party manufacturers; the
success of competing therapies or products that are or may become
available; our ability to attract and retain key scientific or
management personnel; our ability to identify additional product
candidates with significant commercial potential consistent with
our commercial objectives; and our estimates regarding expenses,
future revenue, capital requirements and needs for additional
financing. We have based these forward-looking statements largely
on our current expectations and projections about future events and
trends that we believe may affect our financial condition, results
of operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230821059840/en/
David Snyder, CFO- Coya Therapeutics, Inc.
david@coyatherapeutics.com
Hayden IR: James Carbonara (646)-755-7412 james@haydenir.com
Media Contact Anna Marie Imbordino annamarie@quantum-corp.com
917-680-8765
Coya Therapeutics (NASDAQ:COYA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Coya Therapeutics (NASDAQ:COYA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024